What type of study is this?

This is a Animal Study study (also classified as: Observational).

Phosphoglycerate dehydrogenase interacts with and inhibits the protein kinase TAK1 to mitigate septic shock

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals phosphoglycerate dehydrogenase inhibits TAK1 in macrophages, suggesting new sepsis therapies.

Phosphoglycerate dehydrogenase reduces inflammation in sepsis, mitigating organ damage during septic shock.
Knockdown of PHGDH leads to enhanced inflammatory responses to LPS and E. coli, increasing risk in septic models.
Mechanistic studies show PHGDH inhibits TAK1 binding, thereby suppressing the TAK1-NF-κB/MAPK signaling pathway.
AAV-mediated PHGDH overexpression in macrophages significantly decreases sepsis-related inflammation and damage.

Hu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals phosphoglycerate dehydrogenase inhibits TAK1 in macrophages, suggesting new sepsis therapies.

Phosphoglycerate dehydrogenase reduces inflammation in sepsis, mitigating organ damage during septic shock.
Knockdown of PHGDH leads to enhanced inflammatory responses to LPS and E. coli, increasing risk in septic models.
Mechanistic studies show PHGDH inhibits TAK1 binding, thereby suppressing the TAK1-NF-κB/MAPK signaling pathway.
AAV-mediated PHGDH overexpression in macrophages significantly decreases sepsis-related inflammation and damage.

Hu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark